HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) CME Activity Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fowler, J. S. Articles by Dewey, S. L. Search for Related Content PubMed PubMed Citation Articles by Fowler, J. S. Articles by Dewey, S. L.

PET and Drug Research and Development^*

Chemistry and Medical Departments, Brookhaven National Laboratory, Upton, New York

Correspondence: For correspondence or reprints contact: Joanna S. Fowler, PhD, Chemistry Department, Brookhaven National Laboratory, Upton, NY 11973-5000.

ABSTRACT

The use of PET to examine the behavioral, therapeutic and toxic properties of drugs and substances of abuse is emerging as a powerful new scientific tool. PET provides a new perspective on drug research by virtue of its ability to directly assess both pharmacokinetic and pharmacodynamic events in humans and in animals. These parameters can be assessed directly in the human body both in healthy volunteers and in patients. Moreover, the new generation of high-resolution, small-animal cameras hold the promise of introducing imaging in the early stages of drug development and make it possible to carry out longitudinal studies in animals and to study genetically altered animals. This places PET in a unique position to contribute significantly to the process of drug development through understanding the molecular mechanisms underlying drug action while addressing some very practical questions such as determining effective drug doses for clinical trials for new drugs, determining the duration of drug action and examining potential drug interactions.

Key Words: PET imaging • fluorodeoxyglucose • drug development

FOOTNOTES

^* NOTE: FOR CE CREDIT, YOU CAN ACCESS THIS ARTICLE ON THE SNM WEB SITE (http://www.snm.org) UNTIL JANUARY 2000.

This article has been cited by other articles:

				M.-R. Zhang, K. Kumata, J. Maeda, K. Yanamoto, A. Hatori, M. Okada, M. Higuchi, S. Obayashi, T. Suhara, and K. Suzuki 11C-AC-5216: A Novel PET Ligand for Peripheral Benzodiazepine Receptors in the Primate Brain J. Nucl. Med., November 1, 2007; 48(11): 1853 - 1861. [Abstract] [Full Text] [PDF]

				B. J. Nieman, A. M. Flenniken, S. L. Adamson, R. M. Henkelman, and J. G. Sled Anatomical phenotyping in the brain and skull of a mutant mouse by magnetic resonance imaging and computed tomography Physiol Genomics, January 12, 2006; 24(2): 154 - 162. [Abstract] [Full Text] [PDF]

				A. Bauer, M. H. Holschbach, M. Cremer, S. Weber, C. Boy, N. J. Shah, R. A. Olsson, H. Halling, H. H. Coenen, and K. Zilles Evaluation of 18F-CPFPX, a Novel Adenosine A1 Receptor Ligand: In Vitro Autoradiography and High-Resolution Small Animal PET J. Nucl. Med., October 1, 2003; 44(10): 1682 - 1689. [Abstract] [Full Text] [PDF]

				P. K. Thanos, N. B. Taintor, D. Alexoff, P. Vaska, J. Logan, D. K. Grandy, Y. Fang, J.-H. Lee, J. S. Fowler, and N. D. Volkow In Vivo Comparative Imaging of Dopamine D2 Knockout and Wild-Type Mice with 11C-Raclopride and MicroPET J. Nucl. Med., November 1, 2002; 43(11): 1570 - 1577. [Abstract] [Full Text] [PDF]